NCT03275493View on ClinicalTrials.gov

CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Acute Lymphoblastic LeukemiaCD19 PositiveRelapseRefractory
Interventions
BIOLOGICAL

CD19 CAR-T cells

Express a Second Generation 4-1BB: CD19 CAR-T cells

BIOLOGICAL

CD19 CAR-T cells with CRS suppression technology

Express a Second Generation 4-1BB:CD19 CAR-T cells with CRS suppression technology

Trial Locations (1)

200000

RECRUITING

The first affiliated hospital of soochow university, Suzhou

All Listed Sponsors
collaborator

The First Affiliated Hospital of Soochow University

OTHER

lead

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

INDUSTRY